Mandate

Vinge advises PPR S.A in connection with the sale of Ellos and Jotex

February 25, 2013

Vinge has advised PPR S.A in connection with the sale of Ellos and Jotex to Nordic Capital Fund VII for an enterprise value of €275 million. Ellos is the leading home shopping player in Scandinavia for apparel and Jotex has established itself as a key player in the Scandinavian home textile and decoration market.

PPR S.A is one of the world’s leading apparel and accessories groups that operates in the two fastest growing market segments: Luxury and Sport & Lifestyle. The PPR Group has built a balanced collection of complementary consumer brands, including for example Gucci, Bottega Veneta, Saint Laurent, Alexander McQueen, Stella McCartney, Sergio Rossi, Girard-Perregaux, Puma and Tretorn. Present in more than 120 countries, the PPR Group generated revenues of €9.7 billion in 2012 and had over 33,000 employees at year end. The PPR share is listed on Euronext Paris.

The transaction is subject to approval of relevant competition authorities.

Vinge’s team consisted of responsible partner Johan Winnerblad together with, among others, Christina Kokko (partner) and associates Joacim Rydergård, Alex Miler, Eric Ödling, Karl Hahtovirta and project assistant Annika Johnson.

 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026